AIMA
AIMA provides clinically validated, non-opioid pelvic pain relief through its OVY Relief line of vaginal suppositories and daily capsules. The plant-based formulations target pain at its source for conditions like endometriosis, PCOS, and post-cancer treatment discomfort, with products trusted by over 700 practitioners and available via subscription with 20% savings.
- Healthcare Technology
- Consumer Goods
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Pelvic pain, including conditions like endometriosis, PCOS, and post-cancer treatment discomfort, is a widespread but often overlooked health issue. Many patients rely on opioids or over-the-counter anti-inflammatories like ibuprofen, which can cause digestive issues or lead to dependency, leaving a significant gap for safe, effective, long-term pain management options.
Solution
AIMA offers the OVY Relief line, a set of clinically validated, non-opioid treatments designed to target pelvic pain at its source. The product range includes vaginal suppositories and daily capsules formulated with plant-based science, providing targeted relief for women experiencing chronic pelvic pain. AIMA is partnering with healthcare systems to expand access to its commercialized products across the U.S. and Australia, while also building a pipeline of patent-protected therapies to reshape the future of women's pain management.
Target Audience
Primary customers are women suffering from chronic pelvic pain conditions such as endometriosis, PCOS, perimenopause symptoms, and post-cancer treatment pain, as well as the healthcare practitioners and naturopaths who recommend these treatments.
Features
- OVY Relief Suppositories (5ct) and Pack of 2 (10ct) for targeted vaginal delivery, available at $35.99 and $69.69 respectively
- OVY Relief Daily Capsules (30ct) for systemic daily support, priced at $69.66
- OVY Relief Kit combining both delivery formats at $105.99
- Plant-based, science-driven formulations with clinical assessment, validated by 700+ practitioners
- Subscription model offering 20% off, priority delivery, and automatic refills for personalized ongoing care
- Patent-protected product pipeline with clinically assessed therapies in development for future women's health solutions